Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System – Diagnostic and Interventional Cardiology

February 27, 2024 Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with theGen 2 Aria CVPulmonary Hypertension System as part of theASPIRE PHclinical trial at Ascension St. VincentCardiovascular Research Institute in Indianapolis, Indiana. The implant was completed on February 14, 2024, by Drs. Ashwin Ravichandran and Scott Hittinger.

The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. Arias device is designed to restore the benefits of a healthy pulmonary artery by reducing cardiac workload and enhancing blood flow through the lungs.

The successful patient implant of the Gen 2 system is a significant milestone in realizing our mission to improve the lives of those suffering from pulmonary hypertension, a life-threatening disease that can lead to heart failure, said Dan Gladney, President and CEO of Aria CV. This procedure is a testament to the dedicated ASPIRE PH team that is providing patients with a novel therapeutic option to treat this deadly condition. If approved, this technology has the potential to be lifesaving and lifechanging for thousands of patients with pulmonary hypertension.

The ASPIRE PH trial is a feasibility study assessing the initial safety, tolerability, and efficacy of the Aria System underFood and Drug Administrations (FDA) Early Feasibility Study Program. This program is intended to expedite development of novel medical devices.

We are proud to have performed the first implant of this novel device, as it offers an alternative treatment for patients who remain significantly impacted by right heart dysfunction related to pulmonary hypertension, which has limited approved therapy options, said Dr. Ashwin Ravichandran of Ascension St. VincentHospital Cardiovascular Institute, one of the surgeons whoperformed the procedure.

Pulmonary hypertension (PH), which impacts up to 70 million people worldwide, is characterized by high blood pressure in the arteries of the lungs, a condition which causes increased workload on the heart, leading to right heart failure. PH can be caused by common conditions such as COPD or left heart failure, and can occur without any identified underlying cause and is considered a progressive deadly disease.

For more information:www.ariacv.com

Visit link:
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System - Diagnostic and Interventional Cardiology